Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas | Zendy

Misu Lee | Zendy; Tobias Wiedemann | Zendy; Claudia Groß | Zendy; Ines Leinhäuser | Zendy; Federico Roncaroli | Zendy; Rickmer Braren | Zendy; Natalia S. Pellegata | Zendy

AI Assistant Blog Pricing

Open Access

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas

Author(s) -

Misu Lee,

Tobias Wiedemann,

Claudia Groß,

Ines Leinhäuser,

Federico Roncaroli,

Rickmer Braren,

Natalia S. Pellegata

Publication year - 2015

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-15-0288

Subject(s) - pi3k/akt/mtor pathway , cancer research , apoptosis , in vivo , medicine , cytotoxic t cell , biology , endocrinology , in vitro , biochemistry , microbiology and biotechnology

Novel therapeutic approaches are needed to improve the postoperative management of residual nonfunctioning pituitary adenomas (NFPA), given their high relapse rate. Here, we evaluated the antitumor efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in the only available model of spontaneous NFPAs (MENX rats).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog